Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)

PHASE2CompletedINTERVENTIONAL
Enrollment

477

Participants

Timeline

Start Date

November 6, 2013

Primary Completion Date

August 18, 2015

Study Completion Date

September 16, 2015

Conditions
Heart Failure
Interventions
DRUG

Vericiguat (BAY1021189) (1.25 mg)

1.25 mg BAY1021189 tablets

DRUG

Vericiguat (BAY1021189) (5 mg)

5 mg BAY1021189 tablets

DRUG

Placebo

Trial Locations (158)

220

New Taipei City

813

Kaohsiung City

1090

Vienna

1097

Budapest

1200

Bruxelles - Brussel

1202

Sofia

1205

Geneva

1220

Vienna

1233

Sofia

1309

Sofia

1527

Sofia

2010

Darlinghurst

2400

Mol

2800

Mechelen

3100

Sankt Pölten

4010

Linz

4020

Redcliffe

Linz

4029

Brisbane

4064

Brisbane

4300

Holbæk

4500

Huy

5020

Salzburg

6000

Stara Zagora

6060

Gilly

6900

Lugano

7000

Hobart

8000

Bruges

Székesfehérvár

8018

Burgas

8036

Graz

8800

Roeselare

8930

Randers

9000

Ghent

Aalborg

10016

Taipei

10034

Prague

11217

Taipei

11527

Athens

12462

Chaïdári

12808

Prague

14215

Buffalo

15212

Pittsburgh

17475

Greifswald

20017

Milan

20149

Milan

20246

Hamburg

24127

Bergamo

25123

Brescia

27100

Pavia

28222

Majadahonda

29425

Charleston

30120

El Palmar

30625

Hanover

31201

Macon

31403

Toulouse

33308

Fort Lauderdale

33604

Pessac

34102

Naples

38138

Germantown

39008

Santander

46010

Valencia

46026

Valencia

48149

Münster

48202

Detroit

50937

Cologne

52040

Arezzo

52242

Iowa City

53215

Milwaukee

55422

Minneapolis

60126

Ancona

61348

Bad Homburg

66421

Homburg

69677

Bron

76031

Rouen

79189

Bad Krozingen

80331

München

92708

Fountain Valley

99089

Erfurt

119228

Singapore

169609

Singapore

308433

Singapore

333423

Taoyuan District

768828

Singapore

1528001

Tiberias

1834111

Afula

3109601

Haifa

3810101

Hadera

4941492

Petah Tikva

6423906

Tel Aviv

7030000

Zrifin

7610001

Rehovot

7830604

Ashkelon

9103102

Jerusalem

60611-2908

Chicago

70112-1396

New Orleans

39216-4505

Jackson

07103

Newark

37232-8802

Nashville

M5B 1W8

Toronto

H1T 1C8

Montreal

H2W 1T8

Montreal

J3A 1C3

Saint-Jean-sur-Richelieu

J1G 2E8

Sherbrooke

G1V 4G5

Québec

767 01

Kroměříž

140 21

Prague

169 02

Prague

142 33

Nea Ionia / Athens

H-2143

Kistarcsa

820-8505

Iizuka

670-0981

Himeji

311-3193

Higashiibaraki

920-8650

Kanazawa

760-0018

Takamatsu

252-5188

Sagamihara

236-0051

Yokohama

238-8567

Yokosuka

611-0041

Uji

902-8511

Naha

599-8247

Sakai

569-1096

Takatsuki

773-8502

Komatsushimachō

152-8902

Meguro-ku

106-0031

Minato-ku

910-8526

Fukui

734-8530

Hiroshima

862-8505

Kumamoto

850-8555

Nagasaki

558-8558

Osaka

770-8539

Tokushima

930-8550

Toyama

1105 AZ

Amsterdam

8441 PW

Heerenveen

8934 AD

Leeuwarden

8601 ZR

Sneek

15-276

Bialystok

31-121

Krakow

31-202

Krakow

92-213

Lodz

93-513

Lodz

10-010

Olsztyn

61-848

Poznan

70-965

Szczecin

2801-951

Almada

1449-005

Lisbon

1500-650

Lisbon

1649-035

Lisbon

138-736

Seoul

08003

Barcelona

08023

Barcelona

251 87

Helsingborg

652 30

Karlstad

581 85

Linköping

701 85

Örebro

118 83

Stockholm

S44 5DX

Chesterfield

SG1 4AB

Stevenage

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY

NCT01951638 - Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED) | Biotech Hunter | Biotech Hunter